Evidence map›Paper›PMID 28487567›Full record

ArticleScientific reports2017

A robust in vitro model for trans-lymphatic endothelial migration.

Yanbao Xiong, C Colin Brinkman, Konrad S Famulski, Emmanuel F Mongodin, Colin J Lord, Keli L Hippen, Bruce R Blazar, Jonathan S Bromberg

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 34 citations in OpenAlex.

  1. Lipoxins modulate neutrophil oxidative burst, integrin expression and lymphatic transmigration differentially in human health and atherosclerosis.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2022
    Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Yanbao XiongCenter for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore, USA.
C Colin BrinkmanCenter for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore, USA.
Konrad S FamulskiAlberta Transplant Applied Genomics Centre, University of Alberta, Edmonton, Canada.
Emmanuel F MongodinInstitute for Genome Sciences, University of Maryland School of Medicine, Baltimore, USA.
Colin J LordUniversity of Minnesota Cancer Center and the Department of Pediatrics, Division of Blood and Marrow Transplantation, University of Minnesota, Minneapolis, 55455, USA.
Keli L HippenUniversity of Minnesota Cancer Center and the Department of Pediatrics, Division of Blood and Marrow Transplantation, University of Minnesota, Minneapolis, 55455, USA.
Bruce R BlazarUniversity of Minnesota Cancer Center and the Department of Pediatrics, Division of Blood and Marrow Transplantation, University of Minnesota, Minneapolis, 55455, USA.
Jonathan S BrombergCenter for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore, USA. jbromberg@smail.umaryland.edu.
University of Maryland, Baltimore · USMasonic Cancer CenterUniversity of Alberta · CA

Funding

Trial Design and Biostatistical Support CoreP01CA065493 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI J SUNIL RAO · 1995 to 2026
$48.2M
Transgenic/KnockoutP01AI056299 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI BLAZAR, BRUCE R · 2003 to 2023
$42.5M
Project 3: Humoral Targets and B Cell Biology in Chronic Graft-vs.-Host DiseaseP01CA142106 · NCI · DANA-FARBER CANCER INST · PI RITZ, JEROME · 2009 to 2019
$17.5M
Enhancing Treg Therapeutic Efficacy in GVHDR01HL118979 · NHLBI · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, HIPPEN, KELI L · 2014 to 2025
$6.7M
IN VIVO PREVENTION OF MURINE GVHDR01AI034495 · NIAID · UNIVERSITY OF MINNESOTA TWIN CITIES · PI BLAZAR, BRUCE R · 1993 to 2016
$6.2M
Induction and Migration of Regulatory T Cells: Role of LymphotoxinR01AI062765 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI BROMBERG, JONATHAN S · 2005 to 2019
$5.6M
T-CELL TARGETING FOR GVHDR01HL056067 · NHLBI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI BLAZAR, BRUCE R · 1995 to 2022
$5.4M
In Vivo Prevention of Murine GVHDR37AI034495 · NIAID · UNIVERSITY OF MINNESOTA · PI Bruce R Blazar · 2017 to 2026
$5.4M
GVL TO REDUCE AML RELAPSE AFTER MURINE ALLOGENEIC BMTR01CA072669 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI BLAZAR, BRUCE R · 1997 to 2017
$4.9M
Lymph Node Structure and Function in Tolerance: Role of LamininsR01AI114496 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI BROMBERG, JONATHAN S · 2015 to 2024
$4.2M
Regulatory T Cells and Lymphatic Endothelial Cells: Regulatory Interactions for Migration and SuppressionR37AI062765 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI Jonathan S Bromberg · 2021 to 2026
$2.9M
NCI NIH HHS P01 CA065493NCI NIH HHS P01 CA142106NCI NIH HHS R01 CA072669NHLBI NIH HHS R01 HL056067NHLBI NIH HHS R01 HL118979NIAID NIH HHS P01 AI056299NIAID NIH HHS R01 AI034495NIAID NIH HHS R01 AI062765NIAID NIH HHS R01 AI114496NIAID NIH HHS R37 AI034495NIAID NIH HHS R37 AI062765
6 · The paper itself

Abstract

Trans-endothelial migration (TEM) is essential for leukocyte circulation. While much is known about trans-blood endothelial migration, far less is known about trans-lymphatic endothelial migration. We established an in vitro system to evaluate lymphatic TEM for various cell types across primary mouse and human lymphatic endothelial cells (LEC), and validated the model for the murine LEC cell line SVEC4-10. T cells exhibited enhanced unidirectional migration from the basal (abluminal) to the apical (luminal) surface across LEC, whereas for blood endothelial cells (BEC) they migrated similarly in both directions. This preferential, vectorial migration was chemotactic toward many different chemoattractants and dose-dependent. Stromal protein fibers, interstitial type fluid flow, distribution of chemokines in the stromal layer, and inflammatory cytokines influenced LEC phenotype and leukocyte TEM. Activated and memory CD4 T cells, macrophages, and dendritic cell (DC) showed chemoattractantΔdriven vectorial migration, while CD8 T cell migration across LEC was not. The system was further validated for studying cancer cell transmigration across lymphatic endothelium. This model for lymphatic TEM for various migrating and endothelial cell types possesses the capacity to be high-throughput, highly reproducible and integrate the complexities of lymphatic biology, stromal variability, chemoattractant distribution, and fluid flow.

Indexed as

Cell MovementModels, BiologicalAnimalsCD4-Positive T-LymphocytesCell Adhesion MoleculesCell Line, TumorCellular MicroenvironmentChemokinesChemotaxisEndothelial CellsEndothelium, LymphaticHumansInflammationMice, Inbred C57BLPhenotypeCell Adhesion MoleculesChemokines

Identifiers

PMID28487567
PMCPMC5431648
OpenAlexW2610682271

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.